Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With multiple generic molecules experiencing treble-digit-percentage price increases in the UK in August, betahistine tablets led the month’s biggest risers, according to WaveData.
After launching the Uzedy long-acting formulation of risperidone in partnership with MedinCell earlier this year, Teva has stressed the “really exciting” product profile of another long-acting antipsychotic from the partnership, olanzapine, while discussing how it will avoid the safety pitfalls of legacy products in the space.
Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.
After a couple of years of heavy downwards pressure on US generics prices, prominent off-patent companies have pointed to a change in the pricing environment as several factors combine to reduce price erosion. Meanwhile, some firms are benefiting from first generic launches as others exit the market altogether, while injectables shortages continue to loom large.
Amid increasing financial pressure from the VPAS rebate scheme and a lack of a national uptake strategy, the BGMA has warned that the UK risks losing its leading position in European biosimilars and could become altogether “economically unviable” for biosimilars suppliers.
July brought UK price spikes for multiple presentations of generic olanzapine orodispersible tablets. Market researcher WaveData reveals the reason behind the increases.
Biosimilars of insulin glargine have failed to capture significant market share since their launch in 2020 as pharmacy benefit managers favor the originator’s higher list price for its associated rebates, according to a report from the Biosimilars Council.
The second quarterly report on the biosimilars industry from Samsung Bioepis has drawn attention to how pricing strategies are being used to enable discounts for adalimumab and insulin glargine.
Amid triple-digit-percentage average price rises for several generic molecules in the UK during June 2023, pantoprazole topped the list.
By offering a detailed quarterly report on the US biosimilars market, Samsung Bioepis is hoping to help drive awareness and understanding, ultimately pushing up utilization, the firm’s US head of market access Tom Newcomer tells Generics Bulletin.
Three presentations of olanzapine orodispersible tablets topped our table of the UK generics market’s Biggest Risers for May 2023.
Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.
Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.
Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
With the first US Humira rival having just hit the market and biosimilars seeing increasing adoption overall, Craig Burton – executive director of the AAM’s Biosimilars Council – tells Generics Bulletin that the US biosimilars market is ‘doing better, but we still have improvements to make.’
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.